Kirkland & Ellis advised Yunkang Group Limited (HKSE: 2325), a leading medical operation service provider in China that offers a full suite of diagnostic testing services for medical institutions, on its global offering and listing on The Stock Exchange of Hong Kong Limited on May 18, 2022.
Yunkang is the fifth largest market player in China’s medical operation services sector. Its main business lines include providing diagnostic outsourcing services and diagnostic testing services for medical institutions alliances as well as for non-medical institutions. The pre-IPO and cornerstone investors in Yunkang’s IPO included SPDB International (Hong Kong) Limited, a company indirectly owned by Shanghai Pudong Development Bank Co., Ltd., Harvest International Premium Value (Secondary Market) Fund SPC (acting on behalf of Harvest High Yield SP) and YHLO (Hong Kong) Limited. The IPO raised approximately $140 million.
The Kirkland team was led by capital markets partners Mengyu Lu and Samantha Peng, with support from capital markets associate Kelvin Li, registered foreign lawyer Bill Feng and other capital markets legal professionals in the region. Debt finance partner Jacqueline Zheng also provided support.